Zosuquidar Promotes Antitumor Immunity by Inducing Autophagic Degradation of PD‐L1

Abstract

Abstract The intracellular distribution and transportation process are essential for maintaining PD‐L1 (programmed death‐ligand 1) expression, and intervening in this cellular process may provide promising therapeutic strategies. Here, through a cell‐based high content screening, it is found that the ABCB1 (ATP binding cassette subfamily B member 1) modulator zosuquidar dramatically suppresses PD‐L1 expression by triggering its autophagic degradation. Mechanistically, ABCB1 interacts with PD‐L1 and impairs COP II‐mediated PD‐L1 transport from ER (endoplasmic reticulum) to Golgi apparatus. The treatment of zosuquidar enhances ABCB1‐PD‐L1 interaction and leads the ER retention of PD‐L1, which is subsequently degraded in the SQSTM1‐dependent selective autophagy pathway. In CT26 mouse model and a humanized xenograft mouse model, zosuquidar significantly suppresses tumor growth and accompanies by increased infiltration of cytotoxic T cells. In summary, this study indicates that ABCB1 serves as a negative regulator of PD‐L1, and zosuquidar may act as a potential immunotherapy agent by triggering PD‐L1 degradation in the early secretory pathway.

Keywords

• ABCB1
• autophagy
• ER retention
• PD‐L1
• zosuquidar